BTIG Calls Palvella’s 21% FDA-Driven Drop a Buying Opportunity
The FDA denied Breakthrough Therapy status for QTORIN. BTIG analysts view the decision as a short-term setback and maintain their Buy rating with a $215 price target.
/ 493 items
#XY Event-Driven Stocks↓
Agios Ends Tebapivat Program in Sickle Cell Disease, Focuses on Mitapivat
Agios Pharmaceuticals announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile.
Karyopharm Shares Plunge After $3.7M Executive Cash Retention Program
RBC calls the drop overdone and sees it as a buying opportunity.
RBC Bullish on Nuvation Bio as Safusidenib Delivers Durable Responses in Glioma with New Phase 3 and Phase 2 Studies
Nuvation Bio reports strong long-term Phase 2 data for safusidenib (52% ORR, 79% PFS) and announces new Phase 3 and Phase 2 studies in IDH1-mutant glioma.
Armata Clears Key FDA Milestone, Prepares AP-SA02 Phase 3 Trial for 2026
Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.
Tempus AI Buys Personalis in $1.5B Deal to Advance Blood-Based Cancer Detection
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.